How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

449 results for

Fetal Fibronectin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Serial transvaginal cervical length measurements and quantitative vaginal fetal fibronectin concentrations did not predict spontaneous preterm birth in low-risk nulliparous women

Serial transvaginal cervical length measurements and quantitative vaginal fetal fibronectin concentrations did not predict spontaneous preterm birth in low-risk nulliparous women Serial transvaginal cervical length measurements and quantitative vaginal fetal fibronectin concentrations did not predict spontaneous preterm birth in low-risk nulliparous women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) length measurements and quantitative vaginal fetal fibronectin concentrations did not predict spontaneous preterm birth in low-risk nulliparous women Article Text Commentary Maternal and child health Serial transvaginal cervical length measurements and quantitative vaginal fetal fibronectin concentrations did not predict spontaneous preterm birth in low-risk nulliparous women Donald Dudley Statistics from Altmetric.com Commentary on: Esplin MS, Elovitz MA, Iams JD, et al . Predictive accuracy

2017 Evidence-Based Medicine (Requires free registration)

2. Post-Policy Implementation Review of Rapid Fetal Fibronectin (fFN) Testing for Preterm Labour in Alberta

Post-Policy Implementation Review of Rapid Fetal Fibronectin (fFN) Testing for Preterm Labour in Alberta Redirecting

2016 Institute of Health Economics

3. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis

Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis Deshpande SN, van Asselt AD, Tomini F, Armstrong N, Allen A, Noake C, Khan K (...) AD, Tomini F, Armstrong N, Allen A, Noake C, Khan K, Severens JL, Kleijnen J, Westwood ME. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. Health Technology Assessment 2013; 17(40): 1-138 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Costs and Cost Analysis; Female; Fibronectins /blood; Humans; Length of Stay; Models, Economic; Obstetric Labor, Premature

Full Text available with Trip Pro

2014 NHS Economic Evaluation Database.

4. Point of care tests to exclude pre-term labour: Quantitative Fetal Fibronectin (fFN) testing for predicting pre-term labour

Point of care tests to exclude pre-term labour: Quantitative Fetal Fibronectin (fFN) testing for predicting pre-term labour App Applic Date o Context at www 1. An appl (fFn) te the Dep fee that version A relate Factor B from Al and con 2. After co effectiv support clinical MSAC verifica but also 3. MSAC cervicov plication Quantita cant: of MSAC c t for decisio w.msac.gov. Purpose o lication req ests for exclu partment of t could be us of the fFN ed applicatio Binding Pro lere Pty Ltd nsidered (...) preterm labour Category 2 – Diagnostic Procedures and Investigations MBS [item number] Preterm testing of a cervical secretion specimen, using a fetal fibronectin point-of-care test, in symptomatic women, for the assessment of threatened preterm labour where gestation is greater than 24 weeks and less than 36 weeks gestation and preterm rupture of membranes (PROM) has been excluded to a maximum of two services per pregnancy where the first test yields a negative result. Fee: $104.00 Benefit 75

2014 Medical Services Advisory Committee

5. Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. (PubMed)

Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. Spontaneous preterm birth is a leading cause of infant mortality. Prediction, largely based on prior pregnancy outcomes, is not possible in women pregnant for the first time.To assess the accuracy of universal screening to predict spontaneous preterm birth in nulliparous women using serial measurements of vaginal fetal fibronectin (...) levels and cervical length.A prospective observational cohort study of nulliparous women with singleton pregnancies, from 8 clinical sites across the United States between October 2010 and May 2014. Women and clinicians were blinded to results unless cervical shortening less than 15 mm was identified.Transvaginal cervical length and quantitative vaginal fetal fibronectin levels were reviewed at 2 study visits 4 or more weeks apart.Spontaneous preterm birth at less than 37 weeks was the primary

Full Text available with Trip Pro

2017 JAMA

6. Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta

Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta Institute of Health Economics Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Institute of Health Economics. Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta. Edmonton: Institute of Health Economics (IHE). 2015 Authors' conclusions The PPIR suggests that the policy decision to adopt fFN testing in Alberta did not achieve the intended aims of reducing unnecessary utilization of health services to achieve health system savings. Physicians placing greater significance

2015 Health Technology Assessment (HTA) Database.

7. Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta

Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta application/octet-stream

2015 Institute of Health Economics

8. Accuracy of fetal fibronectin for assessing preterm birth risk in asymptomatic pregnant women: a systematic review and meta-analysis. (PubMed)

Accuracy of fetal fibronectin for assessing preterm birth risk in asymptomatic pregnant women: a systematic review and meta-analysis. Fetal fibronectin (fFN) is a validated test for assessing risk of preterm birth for women presenting with symptoms. Our aim was to evaluate the accuracy of fFN to detect the risk of preterm birth in asymptomatic women.Searches were conducted to identify studies where fFN was performed in asymptomatic women beyond 22 weeks' gestation. EMBASE, MEDLINE, CINHAL, AMED

Full Text available with Trip Pro

2018 Acta Obstetricia et Gynecologica Scandinavica

9. Prediction of preterm delivery in symptomatic women using placental alpha-microglobulin-1, fetal fibronectin and phosphorylated insulin-like growth factor-binding protein-1 tests: systematic review and meta-analysis stratified by risk. (PubMed)

Prediction of preterm delivery in symptomatic women using placental alpha-microglobulin-1, fetal fibronectin and phosphorylated insulin-like growth factor-binding protein-1 tests: systematic review and meta-analysis stratified by risk. To assess the accuracy of placental alpha microglobulin-1 (PAMG-1), fetal fibronectin (fFN) and phosphorylated insulin-like growth factor-binding protein-1 (phIGFBP-1) tests in predicting spontaneous preterm birth (sPTB) within 7 days of testing in women

2018 Ultrasound in Obstetrics and Gynecology

10. Accuracy of fetal fibronectin for the prediction of preterm birth in symptomatic twin pregnancies: a pilot study (PubMed)

Accuracy of fetal fibronectin for the prediction of preterm birth in symptomatic twin pregnancies: a pilot study Our goal was to evaluate the performance of fetal fibronectin (fFN) test alone or combined with cervical length (CL), to predict spontaneous preterm birth (PTB) in symptomatic twin pregnancies. We carry out a short pilot study including all uncomplicated diamniotic twin pregnancies with symptoms of preterm labor (PTL) and intact membranes at 24-33 weeks + 6 days of gestation. Studied

Full Text available with Trip Pro

2018 Scientific reports

11. Exploring fetal fibronectin testing as a predictor of labour onset: In parturient women from isolated communities (PubMed)

Exploring fetal fibronectin testing as a predictor of labour onset: In parturient women from isolated communities To investigate whether the fetal fibronectin assay would be useful for determining if a woman was close to a term delivery. If effective, this test would allow parturient women to stay in their communities longer.This feasibility study used a prospective cohort design to examine the negative predictive value of the fetal fibronectin test at term.Iqaluit, NU.A total of 30 parturient (...) women from rural and isolated communities in Nunavut.Starting at 36 weeks' gestation, women were tested every 2 days, and after 39 weeks this increased to every day until labour.The negative predictive value of the fetal fibronectin test was assessed.Women were no more likely to give birth at 7 or more days after their last negative fetal fibronectin test result relative to their likelihood of giving birth at 6 or fewer days after their last negative test result. Hence, the presence of fetal

Full Text available with Trip Pro

2018 Canadian Family Physician

12. Retrospective cohort study of PAMG-1 and fetal fibronectin test performance in assessing spontaneous preterm birth risk in symptomatic women attending an emergency obstetrical unit. (PubMed)

Retrospective cohort study of PAMG-1 and fetal fibronectin test performance in assessing spontaneous preterm birth risk in symptomatic women attending an emergency obstetrical unit. To compare the performance of the placental alpha microglobulin-1 (PAMG-1) and fetal fibronectin (fFN) tests for the prediction of spontaneous preterm delivery in patients presenting to an emergency obstetric unit with threatened preterm labor, by conducting a retrospective audit of patient medical records from

2017 Ultrasound in Obstetrics and Gynecology

13. Current perspectives on the use of fetal fibronectin testing in preterm labor diagnosis and management. (PubMed)

Current perspectives on the use of fetal fibronectin testing in preterm labor diagnosis and management. One in 10 infants in the United States is delivered preterm (ie, before the 37th week of pregnancy), contributing to the significant burden on the national healthcare system. Nevertheless, a lack of agreement continues among obstetric professional societies on guidelines for standardization of the approach to the diagnosis and management of patients with symptoms of preterm labor (PTL (...) ). This disparity in consensus has likely resulted in poor identification of women at an increased risk for preterm birth (PTB). This paper presents an overview of several clinical guidelines and recommendations from a variety of studies regarding the use of fetal fibronectin (fFN) testing and transvaginal ultrasound (TVU) cervical length measurement, 2 tools that are used to assess the risk of spontaneous PTB (sPTB) in women with symptoms of PTL. We identify areas of commonality and discord within

2017 American Journal Of Managed Care

14. Fetal fibronectin testing and pregnancy outcomes among Texas Medicaid patients at risk for preterm birth. (PubMed)

Fetal fibronectin testing and pregnancy outcomes among Texas Medicaid patients at risk for preterm birth. Fetal fibronectin (fFN) testing between the 24th and 34th weeks of pregnancy in patients with symptomatic preterm labor (PTL) helps assess the risk of spontaneous preterm birth (sPTB), yet the extent of its use is unknown. We assessed use of fFN testing among Texas Medicaid enrollees with symptomatic PTL and evaluated time to infant delivery and healthcare utilization/costs.Retrospective

2017 American Journal Of Managed Care

15. Placental Alpha Microglobulin-1 Compared With Fetal Fibronectin to Predict Preterm Delivery in Symptomatic Women. (PubMed)

Placental Alpha Microglobulin-1 Compared With Fetal Fibronectin to Predict Preterm Delivery in Symptomatic Women. To compare the rapid bedside test for placental α microglobulin-1 with the instrumented fetal fibronectin test for prediction of imminent spontaneous preterm delivery among women with symptoms of preterm labor.We conducted a prospective observational study on pregnant women with signs or symptoms suggestive of preterm labor between 24 and 35 weeks of gestation with intact membranes (...) and cervical dilatation less than 3 cm. Participants were prospectively enrolled at 15 U.S. academic and community centers. Placental α microglobulin-1 samples did not require a speculum examination. Health care providers were blinded to placental α microglobulin-1 results. Fetal fibronectin samples were collected through speculum examination per manufacturer requirements and sent to a certified laboratory for testing using a cutoff of 50 ng/mL. The coprimary endpoints were positive predictive value (PPV

2017 Obstetrics and Gynecology

16. Bio-functionalized magnetic nanoparticles for the immunoassay of fetal fibronectin: a feasibility study for the prediction of preterm birth (PubMed)

Bio-functionalized magnetic nanoparticles for the immunoassay of fetal fibronectin: a feasibility study for the prediction of preterm birth Preterm birth is an important cause of perinatal morbidity and mortality. Various biomarkers in cervicovaginal secretions related to preterm birth have been investigated, of which foetal fibronectin (fFN) shows the greatest potential because of its high negative predictive value. The immunomagnetic reduction (IMR) assay has emerged as a novel quantitative

Full Text available with Trip Pro

2017 Scientific reports

17. Predicting preterm birth: Cervical length and fetal fibronectin (PubMed)

Predicting preterm birth: Cervical length and fetal fibronectin Spontaneous preterm birth remains the leading cause of neonatal morbidity and mortality worldwide, and accounts for a significant global health burden. Several obstetric strategies to screen for spontaneous preterm delivery, such as cervical length and fetal fibronectin measurement, have emerged. However, the effectiveness of these strategies relies on their ability to accurately predict those pregnancies at increased risk (...) for spontaneous preterm birth (SPTB). Transvaginal cervical shortening is predictive of preterm birth and when coupled with appropriate preterm birth prevention strategies, has been associated with reductions in SPTB in asymptomatic women with a singleton gestation. The use of qualitative fetal fibronectin may be useful in conjunction with cervical length assessment in women with acute preterm labor symptoms, but data supporting its clinical utility remain limited. As both cervical length and qualitative

Full Text available with Trip Pro

2017 Seminars in perinatology

18. Utilization of fetal fibronectin testing and pregnancy outcomes among women with symptoms of preterm labor (PubMed)

Utilization of fetal fibronectin testing and pregnancy outcomes among women with symptoms of preterm labor To identify pregnant health plan members triaged through the emergency department (ED), including labor and delivery (ELD) units, with symptoms of preterm labor (PTL), and evaluate the use of fetal fibronectin (fFN) testing; and to calculate the rate of hospitalization and timing of delivery in relation to the ED visit.Retrospective cohort study using Medical Outcomes Research

Full Text available with Trip Pro

2017 ClinicoEconomics and Outcomes Research: CEOR

19. Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion

Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02694198 Recruitment Status : Completed First Posted : February 29, 2016 Results First Posted : April 6, 2016 Last Update Posted : May 16, 2016 Sponsor: Ain

2016 Clinical Trials

20. Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: a systematic review and metaanalysis of randomized controlled trials. (PubMed)

Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: a systematic review and metaanalysis of randomized controlled trials. Fetal fibronectin is an extracellular matrix glycoprotein that is produced by amniocytes and cytotrophoblasts and has been shown to predict spontaneous preterm birth.The aim of this systematic review and metaanalysis of randomized clinical trials was to evaluate the effect of the use of fetal fibronectin (...) in the prevention of preterm birth in singleton pregnancies with threatened preterm labor.The research was conducted with the use of MEDLINE, EMBASE, Web of Sciences, Scopus, ClinicalTrial.gov, OVID, and Cochrane Library as electronic databases from the inception of each database to February 2016. Selection criteria included randomized clinical trials of singleton gestations with threatened preterm labor that were assigned randomly to management based on fetal fibronectin results (ie, intervention group

2016 American Journal of Obstetrics and Gynecology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>